A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers

Inclusion Criteria: * Participant must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed * Participant must have diagnosis of cancer that is advanced or metastatic * Participant must have discontinued previous treatments for cancer and recovered from the acute effects of that therapy * If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug * If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breast feeding Exclusion Criteria: * Participant must not have symptomatic central nervous system malignancy or metastasis * Participant must not have current hematologic malignancy * Participant must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C * Participant must not have a serious cardiac condition